Walleye Capital’s Roivant Sciences ROIV Stock Holding History

Walleye Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$144K	Sell	5,200 -81,300	-94%	-$2.09M	﹤0.01%	3519
2025 Q4	$1.88M	Sell	86,500 -1,900	-2%	-$37.5K	0.01%	1929
2025 Q3	$1.34M	Buy	88,400 +76,500	+643%	+$947K	0.01%	1871
2025 Q2	$134K	Buy	+11,900	New	+$129K	﹤0.01%	3620
2025 Q1	–	Sell	-42,300	Closed	-$500K	–	5009
2024 Q4	$500K	Sell	42,300 -8,000	-16%	-$94.6K	﹤0.01%	2980
2024 Q3	$580K	Sell	50,300 -36,000	-42%	-$410K	﹤0.01%	3156
2024 Q2	$912K	Buy	86,300 +74,600	+638%	+$817K	﹤0.01%	2942
2024 Q1	$123K	Buy	+11,700	New	+$126K	﹤0.01%	4276

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Capital's ROIV Position: Q1 2026 in Review

Walleye Capital increased its Roivant Sciences (ROIV) stake by 211% in Q1 2026, buying an estimated $2.69M and bringing the position to 154,083 shares worth $4.27M. The position accounts for 0.02% of the portfolio, ranked #902.

Walleye Capital first reported a position in ROIV in Q4 2023 and has held it in 6 quarters since. The position peaked at $5.3M in Q4 2023. 439 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

Walleye Capital held 154,083 shares of Roivant Sciences worth $4.27M as of Q1 2026.
Walleye Capital bought 104,593 Roivant Sciences shares in Q1 2026, an estimated $2.69M.
Roivant Sciences made up 0.02% of Walleye Capital's portfolio in Q1 2026, its #902 holding.
Walleye Capital first reported a position in Roivant Sciences in Q4 2023 and has held it in 6 quarters since.
Walleye Capital's Roivant Sciences position peaked at $5.3M in Q4 2023.
439 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.